| Filed On | Filing |
|---|---|
| 10 Nov 2026 |
8-K: Results of Operations and Financial Condition
Positive topline results from Phase 3 Study ‘304’ and positive 12-month data from Phase 2/3 Study ‘302’ position VDPHL01 to potentially become the first oral treatment to receive FDA approval for pattern hair loss in nearly 30 years |
| 09 Nov 2026 |
8-K: Regulation FD Disclosure; Other Events
Study ‘302’ Part B Phase 3 Topline Data in Males with Mild-to-Moderate Pattern Hair Loss November 2026 NOVEMBER 2026 |
| 19 Oct 2026 |
8-K: Regulation FD Disclosure; Other Events
VDPHL01, a novel orally-administered extended-release minoxidil formulation, met all primary and secondary endpoints with high statistical significance in both active treatment arms evaluating once-daily (QD) and twice-daily (BID) admini... |
| 11 Aug 2026 |
8-K: Results of Operations and Financial Condition
Positive topline results from open-label Phase 2 Study ‘207’ evaluating VDPHL01 in female pattern hair loss demonstrated rapid onset and consistent hair growth |
| 15 Jul 2026 |
8-K: Regulation FD Disclosure; Other Events
Study ‘207’ Phase 2 Topline Open Label Data in Females with Mild-to-Moderate Pattern Hair Loss July 2026 |
| 12 May 2026 |
8-K: Results of Operations and Financial Condition
Positive topline results from Phase 2/3 Study ‘302’ position VDPHL01 to potentially become the first FDA-approved oral treatment for pattern hair loss in nearly 30 years |
| 01 May 2026 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities
This Securities Purchase Agreement (this “Agreement”) is dated as of April 29, 2026, between Veradermics, Incorporated, a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including ... |
| 27 Apr 2026 |
8-K: Results of Operations and Financial Condition
Veradermics, Incorporated (the “Company”) reports that it had a preliminary unaudited amount of cash, cash equivalents and marketable securities of approximately $390.8 million as of March 31, 2026. This amount is preliminary and unaudit... |
| 27 Apr 2026 |
8-K: Regulation FD Disclosure; Other Events
Study 302 Phase 2/3 Topline Data in Males with Mild-to-Moderate Pattern Hair Loss April 2026 |
| 30 Mar 2026 |
8-K: Results of Operations and Financial Condition
Veradermics Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Corporate and Clinical Updates |
| 05 Feb 2026 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year
An annual meeting of the stockholders of Veradermics, Incorporated, a Delaware corporation (the “Corporation”), for the election of directors to succeed those whose terms expire and for the transaction of such other business as may prope... |
Loading...